Alpha Antitrypsin Deficiency Market Insight and Market Forecast

Alpha Antitrypsin Deficiency is the most common hereditary disorder in which the body is unable to produce sufficient amounts of Alpha-Antitrypsin (AAT) protein. Alpha-Antitrypsin (AAT) protein plays an important role in protecting organs of the body such as liver and lungs from the harmful effects of proteolytic enzymes such as neutrophil elastase. Thus, AATD leads to increased risk of developing a liver disease like Cirrhosis, as well as lung diseases such as Emphysema and Chronic Obstructive Pulmonary Disease (COPD) and Panniculitis.

As per DelveInsight estimates, total prevalent population of AATD in 6 major markets was found to be 1,835,647 in 2017
Among the EU5 countries, Germany has the highest prevalent population of AATD with 34,345 cases, followed by the United Kingdom, which has a prevalent population of 27,930 in 2017.
Market Size of Alpha antitrypsin deficiency (AATD) in the 6MM was found to be USD 992 million in 2017
Men and women are equally affected by Alpha Antitrypsin Deficiency
The United States accounts for the largest AATD market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain). Among EU5 countries, Germany had the highest market size, while Spain had the lowest market size of ASD.
DelveInsight Analysts have observed the population with PISS allele to have the highest numbers, followed by PISZ. However, the most prevalent type of deficient allele associated with AAT Deficiency is the Z allele.

For more detailed information visit:
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-market